
|Videos|January 9, 2018
Dr. Domchek on Promising Biomarkers in Breast Cancer
Author(s)Susan Domchek, MD
Susan Domchek, MD, director of the Basser Center for BRCA at Penn Medicine, discusses promising biomarkers in breast cancer.
Advertisement
Susan Domchek, MD, director of the Basser Center for BRCA at Penn Medicine, discusses promising biomarkers in breast cancer.
Biomarkers such as BRCA1/2 are currently used to determine treatment for patients with breast cancer, explains Domcheck.
Domcheck adds that if a patient is microsatellite instability-high (MSI-H), then that patient can receive pembrolizumab (Keytruda) regardless of tumor site.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on OncLive
1
Lurbinectedin-Based Triplet Shows Clinical Benefit in Advanced Soft Tissue Sarcoma
2
Ultra-Sensitive ctDNA and CSF Liquid Biopsy May Refine Monitoring and Adaptive Trial Designs in Metastatic Breast Cancer
3
PD-L1 Expression Is More Predictive of Response to Pembrolizumab on Metastatic Sites in High-Grade Serous Ovarian Cancer
4
Anti–Gremlin-1 Therapy Plus Chemo Makes Waves in GI Malignancies
5



































